Overexpression of urokinase-type plasminogen activator in pterygia and pterygium fibroblasts

PURPOSE Urokinase-type plasminogen activator (uPA) is a protease involved in tissue remodeling and cell migration. Little is known about the expression of uPA in pterygium. The purpose of this study was to investigate the expression of uPA mRNA and activities in various stages of surgically excised pterygia specimens and cultured pterygium fibroblasts and to compare them with normal conjunctival tissues and fibroblasts. METHODS The expression of uPA mRNA and activity in 15 pterygium tissues and cultured fibroblasts from pterygium were measured using quantitative RT-PCR and zymography. Five normal conjunctiva specimens and cultured conjunctival fibroblasts were tested as the controls. RESULTS The expression of uPA mRNA and activities in pterygia and pterygium fibroblasts were significantly greater than those of the normal samples (p<0.05) and were closely related to the progression of pterygium. The amounts of uPA mRNA and activities in early, moderate, and advanced pterygia were 100%, 208%, and 311% and 100%, 157%, and 280% of the early stage specimens, respectively. The amounts of uPA mRNA and the activities in cultured pterygium fibroblasts isolated from early, moderate, and advanced pterygium specimens were 100%, 219%, and 457% and 100%, 198% and 355% of early stage fibroblasts, respectively. CONCLUSIONS Overexpression of uPA was present in pterygium and their fibroblasts. The expression of uPA by pterygium increased significantly following the progression of the pterygium. The increased expression of uPA may covert plasminogen to plasmin, degrade extracellular matrixes, stimulate cell migration, induce angiogenesis, and plays an important role in the development and progression of pterygium.

[1]  Mu-Kuan Chen,et al.  Prostaglandin E2/EP1 Signaling Pathway Enhances Intercellular Adhesion Molecule 1 (ICAM-1) Expression and Cell Motility in Oral Cancer Cells* , 2010, The Journal of Biological Chemistry.

[2]  Ahmed H. Mekkawy,et al.  Urokinase plasminogen activator system as a potential target for cancer therapy. , 2009, Future oncology.

[3]  D. Hu,et al.  Increased expression of gelatinase (MMP-2 and MMP-9) in pterygia and pterygium fibroblasts with disease progression and activation of protein kinase C. , 2009, Investigative ophthalmology & visual science.

[4]  S. Sorrenti,et al.  The urokinase plasminogen activator system: a target for anti-cancer therapy. , 2009, Current cancer drug targets.

[5]  R. Hildenbrand,et al.  The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. , 2009, International journal of oncology.

[6]  Aamir Ahmad,et al.  Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.

[7]  J. Gilabert-Estellés,et al.  Fibrinolysis: the key to new pathogenetic mechanisms. , 2008, Current medicinal chemistry.

[8]  S. Chu,et al.  Antimetastatic potentials of flavones on oral cancer cell via an inhibition of matrix-degrading proteases. , 2008, Archives of oral biology.

[9]  M. Ranson,et al.  Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. , 2008, Recent patents on anti-cancer drug discovery.

[10]  D. Wakefield,et al.  The pathogenesis of pterygium: current concepts and their therapeutic implications. , 2008, The ocular surface.

[11]  Yong Li,et al.  Targeting uPA/uPAR in prostate cancer. , 2007, Cancer treatment reviews.

[12]  B. Nielsen,et al.  Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor , 2007, International journal of cancer.

[13]  R. Tsai,et al.  Fibroblasts isolated from human pterygia exhibit transformed cell characteristics , 1994, In Vitro Cellular & Developmental Biology - Animal.

[14]  M. Crippa.  Urokinase-type plasminogen activator. , 2007, The international journal of biochemistry & cell biology.

[15]  E. Yamamoto,et al.  Targeting urokinase-type plasminogen activator and its receptor for cancer therapy , 2006, Anti-cancer drugs.

[16]  Xiangping Liu,et al.  [Expression of matrix metalloproteinase in human pterygia]. , 2004, Yan ke xue bao = Eye science.

[17]  D. Wakefield,et al.  Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases , 2004, Progress in Retinal and Eye Research.

[18]  M. Bologna,et al.  Plasminogen activator system modulates invasivecapacity and proliferation in prostatic tumor cells , 1998, Clinical & Experimental Metastasis.

[19]  D. Wakefield,et al.  UVB-elicited induction of MMP-1 expression in human ocular surface epithelial cells is mediated through the ERK1/2 MAPK-dependent pathway. , 2003, Investigative ophthalmology & visual science.

[20]  Peter F M Choong,et al.  Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. , 2003, Clinical orthopaedics and related research.

[21]  D. Wakefield,et al.  Active matrilysin (MMP-7) in human pterygia: potential role in angiogenesis. , 2001, Investigative ophthalmology & visual science.

[22]  G. Schultz,et al.  Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. , 2001, Archives of ophthalmology.

[23]  S. Tseng,et al.  Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by pterygium head fibroblasts. , 2001, Archives of ophthalmology.

[24]  D. Wakefield,et al.  Differential expression of matrix metalloproteinases and their tissue inhibitors at the advancing pterygium head. , 2000, Investigative ophthalmology & visual science.

[25]  E. Dublin,et al.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. , 2000, The American journal of pathology.

[26]  S. Tseng,et al.  Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. , 2000, Investigative ophthalmology & visual science.

[27]  D. Wakefield,et al.  Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. , 2000, Investigative ophthalmology & visual science.

[28]  D. English,et al.  Sun exposure and pterygium of the eye: a dose-response curve. , 1999, American journal of ophthalmology.

[29]  J. Foekens,et al.  Insulin-like growth factor 1 (IGF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts , 1999, Molecular and Cellular Endocrinology.

[30]  D. Wakefield,et al.  The pathogenesis of pterygia. , 1999, Current opinion in ophthalmology.

[31]  J. Foekens,et al.  Urokinase‐type‐plasminogen‐activator(UPA) production by human breast (myo)fibroblasts in vitro: Influence of transforming growth factor‐β1 (TGFβ1) compared with factor(s) released by human epithelial‐carcinoma cells , 1998, International journal of cancer.

[32]  T. Hattori,et al.  Cellular localization of urokinase‐type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues , 1997, The Journal of pathology.

[33]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[34]  G. V. van Muijen,et al.  The plasminogen activation system in tumour invasion and metastasis. , 1996, Pathology, research and practice.

[35]  S. Tseng,et al.  Three patterns of cytokine expression potentially involved in epithelial‐fibroblast interactions of human ocular surface , 1995, Journal of cellular physiology.

[36]  M. Coroneo.  Pterygium as an early indicator of ultraviolet insolation: a hypothesis. , 1993, The British journal of ophthalmology.

[37]  M. Duffy.  Plasminogen activators and cancer. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[38]  S. Horiguchi,et al.  Pterygium in welders. , 1984, The British journal of ophthalmology.

[39]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[40]  J H HILGERS,et al.  Pterygium: its incidence, heredity and etiology. , 1960, American journal of ophthalmology.